These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 36198436)

  • 21. Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptying--preclinical evidence.
    Werner U
    J Diabetes Complications; 2014; 28(1):110-4. PubMed ID: 23992745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glucagon-like peptide-1 receptor agonists: a narrative review of clinical pharmacology and implications for peri-operative practice.
    Milder DA; Milder TY; Liang SS; Kam PCA
    Anaesthesia; 2024 Jul; 79(7):735-747. PubMed ID: 38740566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of glucagon-like peptide 1 receptor agonists in management of obesity.
    Isaacs D; Prasad-Reddy L; Srivastava SB
    Am J Health Syst Pharm; 2016 Oct; 73(19):1493-507. PubMed ID: 27521241
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mitemcinal (GM-611), an orally active motilin receptor agonist, improves delayed gastric emptying in a canine model of diabetic gastroparesis.
    Onoma M; Ozaki K; Yogo K; Monnai M; Muramatsu H; Kamei K; Kawabe Y; Hayashi S; Shiga T; Matsuo S; Suzuki M; Itoh Z; Omura S; Takanashi H
    Clin Exp Pharmacol Physiol; 2008 Jul; 35(7):788-96. PubMed ID: 18346169
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prucalopride in diabetic and connective tissue disease-related gastroparesis: Randomized placebo-controlled crossover pilot trial.
    Andrews CN; Woo M; Buresi M; Curley M; Gupta M; Tack J; Wilsack L; Nasser Y
    Neurogastroenterol Motil; 2021 Jan; 33(1):e13958. PubMed ID: 32743954
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus.
    Shin A; Camilleri M; Busciglio I; Burton D; Smith SA; Vella A; Ryks M; Rhoten D; Zinsmeister AR
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1453-1459.e4. PubMed ID: 23639598
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report.
    Klein SR; Hobai IA
    Can J Anaesth; 2023 Aug; 70(8):1394-1396. PubMed ID: 36977934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.
    Shaefer CF; Kushner P; Aguilar R
    Postgrad Med; 2015; 127(8):818-26. PubMed ID: 26371721
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes.
    Quast DR; Schenker N; Menge BA; Nauck MA; Kapitza C; Meier JJ
    Diabetes Care; 2020 Sep; 43(9):2137-2145. PubMed ID: 32647054
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Confounding Factors in the Association Between Glucagon-Like Peptide-1 Receptor Agonist Use and Retained Gastric Contents in Asymptomatic Patients Undergoing Upper Gastrointestinal Endoscopy: A Retrospective Study.
    Elimihele TA; Mangrola AM; Oshomoji O; Wilson NB; Nnamani I; Ashong B; Billings S; Getu DK; Kumar S; Maliakkal B
    Cureus; 2024 Sep; 16(9):e69152. PubMed ID: 39398811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of glucagon-like peptide receptor 1 agonist therapy with the presence of gastric contents in fasting patients undergoing endoscopy under anesthesia care: a historical cohort study.
    Wu F; Smith MR; Mueller AL; Klapman SA; Everett LL; Houle T; Kuo B; Hobai IA
    Can J Anaesth; 2024 Jul; 71(7):958-966. PubMed ID: 38485835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.
    Østergaard L; Frandsen CS; Madsbad S
    Expert Rev Clin Pharmacol; 2016; 9(2):241-65. PubMed ID: 26573176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-acting glucagon-like peptide-1 receptor agonists have direct access to and effects on pro-opiomelanocortin/cocaine- and amphetamine-stimulated transcript neurons in the mouse hypothalamus.
    Knudsen LB; Secher A; Hecksher-Sørensen J; Pyke C
    J Diabetes Investig; 2016 Apr; 7 Suppl 1(Suppl 1):56-63. PubMed ID: 27186357
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients.
    Rogliani P; Matera MG; Calzetta L; Hanania NA; Page C; Rossi I; Andreadi A; Galli A; Coppola A; Cazzola M; Lauro D
    Respir Med; 2019; 154():86-92. PubMed ID: 31228775
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
    Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL
    BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantified Metrics of Gastric Emptying Delay by Glucagon-Like Peptide-1 Agonists: A Systematic Review and Meta-Analysis With Insights for Periprocedural Management.
    Hiramoto B; McCarty TR; Lodhia NA; Jenkins A; Elnaiem A; Muftah M; Flanagan R; Chan WW
    Am J Gastroenterol; 2024 Jun; 119(6):1126-1140. PubMed ID: 38634551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Do glucagon-like peptide-1 receptor (GLP-1R) agonists have potential as adjuncts in the treatment of type 1 diabetes?
    Doggrell SA
    Expert Opin Pharmacother; 2018 Oct; 19(15):1655-1661. PubMed ID: 30234389
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
    Gentilella R; Pechtner V; Corcos A; Consoli A
    Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists.
    Urva S; Coskun T; Loghin C; Cui X; Beebe E; O'Farrell L; Briere DA; Benson C; Nauck MA; Haupt A
    Diabetes Obes Metab; 2020 Oct; 22(10):1886-1891. PubMed ID: 32519795
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease.
    Baggio LL; Drucker DJ
    Mol Metab; 2021 Apr; 46():101090. PubMed ID: 32987188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.